BioCryst Pharmaceuticals Inc (BCRX) Stock Analysis
Verdict: WATCH (do not buy)
ORLADEYO revenue momentum and pipeline expansion drive profitability, but negative equity and debt load cap near-term re-rating.
Investment score: 59/100
Analysis as of
Is BioCryst Pharmaceuticals Inc stock worth reviewing? AI model thesis
The model views BioCryst as a HOLD. While ORLADEYO commercial traction generated $104.1M in Q2 2026 free cash flow, substantial leverage and single-product reliance prevent a higher score.
7-factor investment score
- Valuation: 65/100 (weight 20%)
- Financial Health: 60/100 (weight 15%)
- Technical Momentum: 52/100 (weight 15%)
- Earnings Quality: 55/100 (weight 15%)
- Insider Sentiment: 40/100 (weight 10%)
- Analyst Consensus: 75/100 (weight 10%)
- Risk-Adjusted Return: 62/100 (weight 15%)
BioCryst Pharmaceuticals Inc opportunities and risks
What speaks for BCRX
- ORLADEYO Revenue Growth and FY2026 Guidance Expansion
What speaks against BCRX
- Single-Product Revenue Concentration in ORLADEYO
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| BCRX | n/a | 2.4x | n/a | 23.5% | -40.9% | 16.0% |
| IRON | n/a | 0.0x | n/a | 0.0% | 0.0% | -7.4% |
| BEAM | n/a | 16.7x | n/a | 18.9% | -54.7% | -14.3% |
| MLYS | n/a | 0.0x | n/a | 0.0% | 0.0% | -5.5% |
| VERA | n/a | 0.0x | n/a | 0.0% | 0.0% | -13.5% |
| SLS | n/a | 0.0x | n/a | 0.0% | 0.0% | -1.4% |
| Peer median | n/a | 0.0x | n/a | 0.0% | 0.0% | -7.4% |
Frequently asked questions about BioCryst Pharmaceuticals Inc (BCRX)
Is BCRX stock a good investment?
The cached TradeMates AI model rates BioCryst Pharmaceuticals Inc as WATCH (do not buy) with an investment score of 59/100. The model views BioCryst as a HOLD. While ORLADEYO commercial traction generated $104.1M in Q2 2026 free cash flow, substantial leverage and single-product reliance prevent a higher score. This is algorithmic model output, not personal investment advice.
Is BCRX stock a buy?
The TradeMates model verdict for BCRX is WATCH (do not buy) with an investment score of 59/100. Treat this as a model signal to review, not a personal buy recommendation.